Held by 9 specialist biotech funds
High Convergence# Signal Note: Avoro Initiates $243M Position in Xenon Pharmaceuticals Avoro Capital's substantial 5.4M share entry (5.2% stake) signals conviction in Xenon's pipeline, likely driven by upcoming catalysts in its lead programs: XEN496 (FXTAS, a rare neurological disorder) and potentially earlier-stage seizure assets.
AI analyst context — unlock full analysis
# Signal Note: Driehaus Initiates $203M Position in Xenon Pharmaceuticals Driehaus's substantial entry into XENE signals confidence in Xenon's pipeline maturation, likely driven by upcoming catalysts around XEN1101 (voltage-gated potassium channel opener for epilepsy), which showed robust Phase 2 efficacy data and could support a pivotal trial initiation in 2024-2025. The $203M position size—meaningful for a growth manager—suggests conviction in near-term newsflow and commercial potential in a large, underpenetrated epilepsy market with limited competition in this mechanism class.
+ 7 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial